Case Details
- Citation: [2022] SGCA 64
- Title: Saridewi Binte Djamani v Public Prosecutor
- Court: Court of Appeal of the Republic of Singapore
- Date: 6 October 2022
- Judges: Sundaresh Menon CJ; Andrew Phang Boon Leong JCA; Tay Yong Kwang JCA
- Proceedings: Criminal Appeal No 30 of 2018 and Criminal Motion No 15 of 2019
- Related Trial Case: Criminal Case No 28 of 2018 (HC/CC 28/2018)
- Appellant/Applicant: Saridewi Binte Djamani
- Respondent: Public Prosecutor
- Legal Areas: Criminal Law; Misuse of Drugs Act offences; Criminal Procedure; Admissibility of statements; Sentencing (death sentence)
- Statutes Referenced: Misuse of Drugs Act (Cap 185, 2008 Rev Ed) (“MDA”) — ss 5(1)(a), 5(2), 17
- Key Prior Decisions: Public Prosecutor v Saridewi Bte Djamani and another [2018] SGHC 204 (“Main Judgment”); Public Prosecutor v Saridewi bte Djamani [2022] SGHC 150 (“Remittal Judgment”)
- Judgment Length: 16 pages; 3,920 words
- Core Issues: Whether the appellant rebutted the statutory presumption of trafficking under s 17 by proving intended consumption of a particular packet (A1A2A); admissibility/weight of investigative statements in light of alleged methamphetamine withdrawal; threshold for excluding statements
Summary
In Saridewi Binte Djamani v Public Prosecutor ([2022] SGCA 64), the Court of Appeal dismissed both an appeal against conviction and sentence and an application to adduce fresh medical evidence. The appellant, Saridewi, was convicted of possession of diamorphine for the purpose of trafficking under ss 5(1)(a) and 5(2) of the Misuse of Drugs Act (MDA). She was sentenced to death by the High Court.
The central defence was that a substantial portion of the diamorphine was not intended for trafficking but for her own consumption. In particular, she argued that one packet marked A1A2A was meant for her personal use. The Court of Appeal held that the appellant failed to rebut the statutory presumption in s 17 of the MDA. It emphasised that the “key pillar and essential foundation” of a consumption defence is the accused’s rate of consumption, and that the appellant’s evidence did not establish a credible consumption rate sufficient to displace the presumption.
On the procedural side, Saridewi sought to rely on a medical report to show that her state of mind was impaired at the time her statements were taken, thereby undermining the admissibility or reliability of those statements. The Court of Appeal accepted that she had at most moderate methamphetamine withdrawal, but concluded that the psychiatric evidence did not demonstrate that withdrawal affected her ability to give reliable statements. The surrounding observations by doctors and nurses showed she was lucid, coherent, alert, and oriented, and she did not exhibit serious withdrawal manifestations. Accordingly, there was no basis to exclude her statements or to disturb the trial judge’s findings.
What Were the Facts of This Case?
The case arose from a CNB covert operation on 17 June 2016 in the vicinity of Block 350, Anchorvale Road. At about 3.35pm, one Muhammad Haikal Bin Abdullah (“Haikal”) arrived by motorcycle and entered the carpark. After parking, he retrieved a white plastic bag from the motorcycle and took the lift to the 17th floor, where he met Saridewi and handed her a white plastic bag. In exchange, Saridewi gave Haikal an envelope marked “10.000”. The parties then separated.
Shortly after, Haikal was intercepted and arrested by CNB officers. Meanwhile, at about 3.50pm, CNB officers gathered near the unit where Saridewi resided. When she heard their movements and voices outside her door, she suspected the presence of CNB officers and threw various items out of the kitchen window. CNB officers attempted to gain entry by opening the gate, but before they could do so, Saridewi let them into the unit and she was arrested.
A search of the unit and the surrounding vicinity yielded multiple items associated with drug processing and packaging. Officers seized packets of crystalline substance, numerous glass tubes, a slab of tablets, empty packets and straws, unused envelopes, a digital weighing scale, and a heat sealer. They also seized four mobile communication devices and a notebook from Saridewi. From the vicinity of the unit, officers recovered, among other items, a plastic bag arrangement marked A1 containing another plastic bag A1A, which in turn contained two packets A1A1 and A1A2, each containing a packet of granular powdery substance. The recovered exhibits were later analysed by the Health Sciences Authority (HSA).
The HSA analysis showed that the diamorphine in Saridewi’s charge totalled 30.72g, corresponding to the combined diamorphine amounts found in multiple exhibits, including A1A1A and A1A2A. The appellant’s defence focused on the claim that the packet A1A2A (which contained a larger quantity of diamorphine and was alleged to be “better quality”) was intended for her own consumption rather than trafficking. The High Court rejected this defence, and the Court of Appeal later had to assess whether the statutory presumption under s 17 had been rebutted on the evidence, and whether the appellant’s statements were reliable in light of her alleged methamphetamine withdrawal.
What Were the Key Legal Issues?
The first key legal issue was whether Saridewi had rebutted the statutory presumption in s 17 of the MDA. Under s 17, where an accused is found in possession of controlled drugs, the law presumes that the accused possessed the drugs for the purpose of trafficking, unless the accused can rebut the presumption on a balance of probabilities. The Court of Appeal had to determine whether the appellant’s consumption defence—particularly her claim that A1A2A was for personal consumption—was supported by credible evidence.
The second key issue concerned the admissibility and reliability of Saridewi’s investigative statements. Saridewi applied to adduce fresh evidence in the form of a medical report by Dr Rajesh dated 13 July 2019. She argued that the report showed her state of mind was impaired at the time her statements were taken, due to methamphetamine withdrawal, and that this impairment undermined the reliability of her statements. The Court of Appeal had to consider whether the psychiatric evidence justified excluding her statements or otherwise displacing the trial judge’s reliance on them.
Related to both issues was the Court’s approach to consumption defences in drug possession cases. The Court reiterated that the analysis must consider the totality of the circumstances, but it also clarified that the “rate of consumption” is the “key pillar and essential foundation” of such a defence. This affected how the Court evaluated the appellant’s evidence and whether her defence was internally coherent and credible.
How Did the Court Analyse the Issues?
The Court of Appeal began by restating the governing approach to consumption defences under the MDA. It referred to the framework in Muhammad bin Abdullah v Public Prosecutor and another and subsequent clarifications. The Court emphasised that the inquiry is not mechanical; rather, it requires examining the totality of the circumstances to determine whether the accused has rebutted the s 17 presumption. Relevant circumstances include the accused’s rate of consumption, the frequency and typical manner by which the accused obtains supply, affordability at the alleged consumption rate, and whether any admissions in the accused’s statements indicate that the whole quantity was for sale.
Crucially, the Court clarified that the “key pillar and essential foundation” of a consumption defence is the accused’s rate of consumption. Other factors—such as financial ability, how the accused came to be in possession, and the presence of trafficking paraphernalia—are secondary. The Court reasoned that these secondary factors “flow from” the consumption rate; therefore, the rate of consumption is logically anterior to the rest of the analysis. It also reiterated that it is for the accused to establish the alleged consumption rate with credible evidence.
Applying this framework, the Court found that Saridewi’s appeal fell far short of the threshold required to rebut the presumption. While the Court’s extract is truncated, the reasoning reflected in the decision indicates that the appellant’s evidence did not establish a credible consumption rate that could explain the quantity and packaging of diamorphine found. The Court also treated the shifting nature of the appellant’s consumption defence as a significant weakness. In other words, the defence was not presented in a way that was consistent with a stable, evidence-backed consumption pattern.
On the statement admissibility and reliability issue, the Court addressed the fresh psychiatric evidence obtained on remittal. The Court accepted that Saridewi had methamphetamine withdrawal and was prepared to accept that it was moderate, despite slight disagreement between experts. However, the Court held that the evidence did not show that withdrawal affected her ability to give reliable statements. The Court’s analysis focused on whether the psychiatric condition had any practical implications for the appellant’s cognitive functioning at the time of questioning—particularly whether it impaired focus, concentration, or made her suggestible in a way that would undermine the reliability of her statements.
The Court found the defence expert’s explanation insufficiently connected to the appellant’s actual circumstances. Dr Rajesh’s opinion, as described in the judgment, suggested that greater severity of withdrawal could affect cognitive processes such as lack of focus and poor concentration and suggestibility. But the Court noted that Dr Rajesh did not tie these general propositions to Saridewi’s specific claims, did not identify which parts of the statements should be disregarded, and did not explain how the appellant’s consumption defence had shifted over time. This lack of specificity mattered because the legal question was not whether withdrawal can theoretically affect cognition, but whether it did so in a manner that undermined the reliability of the statements in this case.
Most importantly, the Court relied on contemporaneous clinical observations. The doctors and nurses who assessed Saridewi at the time did not observe serious withdrawal manifestations. Saridewi did not raise complaints or exhibit symptoms of drug withdrawal to the four doctors who assessed her. The medical staff did not observe noticeable signs of distress. Instead, Saridewi was able to respond and communicate lucidly and coherently, and she was observed to be alert and oriented. These observations supported the trial judge’s conclusion that there was no basis to exclude all her statements.
In light of these findings, the Court of Appeal concluded that the trial judge did not err in his approach to the statements. It also endorsed the remittal judge’s conclusion that even if withdrawal existed at a moderate level, the totality of the further evidence did not affect the earlier findings and rulings regarding the appellant’s statements and guilt. The Court therefore saw no reason to depart from the High Court’s conclusion on the appellant’s culpability.
What Was the Outcome?
The Court of Appeal dismissed the appeal against conviction and sentence. It held that the appellant failed to rebut the presumption under s 17 of the MDA. Accordingly, the conviction for possession of diamorphine for the purpose of trafficking stood, and the death sentence imposed by the High Court remained undisturbed.
The Court also dismissed Criminal Motion No 15 of 2019. The Court found that the fresh medical evidence did not establish that Saridewi’s methamphetamine withdrawal impaired her ability to give reliable statements, and therefore did not justify excluding her statements or undermining the trial judge’s reliance on them.
Why Does This Case Matter?
This decision is significant for practitioners because it reinforces the structured approach to consumption defences under the MDA and clarifies the analytical primacy of the “rate of consumption”. While courts consider a range of contextual factors, Saridewi underscores that without credible evidence of the consumption rate, secondary factors are unlikely to carry the defence. This is particularly important in cases where the accused attempts to argue that only part of the drugs was for personal use. The Court’s reasoning suggests that such partial consumption narratives must still be anchored in a coherent, evidence-based consumption rate that can plausibly account for the quantity and circumstances of possession.
From a procedural standpoint, the case also provides guidance on how psychiatric or medical evidence should be assessed when it is used to challenge the reliability of investigative statements. The Court did not treat the existence of withdrawal symptoms as automatically determinative. Instead, it required a specific demonstration of how the condition affected the accused’s ability to provide reliable statements at the relevant time. Contemporaneous clinical observations by medical professionals were treated as highly persuasive, especially where the accused did not exhibit serious withdrawal manifestations and was assessed as lucid and oriented.
For law students and litigators, the case illustrates the importance of evidential linkage. Expert reports that remain at a general level—without identifying specific cognitive impairments, specific statement segments, or a clear causal connection to the accused’s actual condition—may be insufficient to displace trial findings. The decision therefore serves as a practical reminder that both substantive and procedural defences under the MDA demand credible, case-specific evidence rather than broad theoretical propositions.
Legislation Referenced
- Misuse of Drugs Act (Cap 185, 2008 Rev Ed) — s 5(1)(a)
- Misuse of Drugs Act (Cap 185, 2008 Rev Ed) — s 5(2)
- Misuse of Drugs Act (Cap 185, 2008 Rev Ed) — s 17
Cases Cited
- [2003] SGCA 17
- [2017] 1 SLR 427
- [2018] SGHC 204
- [2021] 1 SLR 557
- [2022] SGCA 39
- [2022] SGCA 64
- [2022] SGHC 150
Source Documents
This article analyses [2022] SGCA 64 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.